By Jens Leutloff, Senior Consultant Email jleutloff@partner4access.com The discussion of cost containment measures in the German healthcare system does not seem to stop, and could gain new momentum after Germany’s federal election in September. Once again, the idea to shorten the free pricing period in Germany was raised recently. During a virtual event celebrating 10…
By Andrea Bernardini, Analyst & Akshay Kumar, Partner Email: abernardini@partners4access.com akumar@partners4access.com On the 12th of February the Orphan Drugs Observatory and the Italian Society of Hospital Pharmacy and Pharmaceutical Services for Healthcare (OSSFOR) have produced the 5th Report on orphan drugs receiving Innovative Status by AIFA in Italy. Although AIFA’s algorithm for assigning innovation status…
By Chloe Sheppard, Senior Analyst & Max Rex, Consultant Email: csheppard@partners4access.com mrex@partners4access.com Cost-effectiveness analyses, as part of Health Technology Assessments (HTAs) for new therapies, appear to be growing in importance across Europe. These analyses are already required in many markets within and outside of Europe for HTAs, including Canada, England, and the Netherlands. In future,…
Why embrace them? By Chloe Sheppard, Erfan Akbraian, Andrea Bernardini & Richard Wang Advanced Therapy Medicinal Products (ATMPs) have significant potential to transform the lives of patients by delivering remarkable, durable improvements in clinical outcomes, in addition to providing long-term cost-savings to healthcare budgets. Manufacturers often face challenges with securing reimbursement and access for high-cost…
By Erfan Akbraian, Analyst Email: eakbraian@partners4access.com On World Cancer Day, 4th February 2021, President Emmanuel Macron announced France’s 10-year Cancer plan1. His predecessors have rolled out these strategies before, but they have been mid-term 5-year strategies. France has taken on board previous cancer plan insights and built an ambitious holistic 10-year strategy now. The plan…
By Akshay Kumar, Partner & Andrea Bernardini, Analyst Email: akumar@partners4access.com abernardini@partners4access.com In the latest guidelines for Pricing and Reimbursement (P&R) dossier submissions, Italian Medicines Agency (AIFA) requires manufacturers to self-report prices, including the percentage discounts and/or Management Entry Agreements (MEAs) agreed with other EU countries and the UK. If these are confidential agreements, AIFA in…
By Erfan Akbraian, Analyst Email: eakbraian@partners4access.com In recent years there have been discussions to shift to a multi-stakeholder approach and increase early communication amongst key stakeholders to ensure appropriate access of advanced therapy medicinal products (ATMPs). With an increasing number of ATMPs for orphan diseases in the pipeline, there is a need for health technology…
By Akshay Kumar, Partner & Andrea Bernardini, Analyst Email: akumar@partners4access.com abernardini@partners4access.com Bulgaria introduced multiple reforms to their healthcare system since 2011. This included the introduction of health technology assessments in 2015. However, evidence has shown that these reforms have had so far little impact on improving effectiveness of care, patient access to treatments or cost containment. …
Are they as beneficial to manufacturers as they seem? By Joana Fernandes & Ashkay Kumar What are the research aims? Products that are being reviewed by the BeNeLuxA and FiNoSe joint initiatives often generate a lot of media attention and interest for those in the pharma world. But what do these initiatives actually entail, and…
Leading specialist market access consultancy Partners4Access (P4A) is to host a free webinar to share insights on key 2021 trends in market access for pharma/biotech manufacturers. The webinar titled ` EU Market Access 2021:What’s in store for Orphan Drugs and ATMPs?’ will be conducted by educational webinars provider Xtalks and will be held on Wednesday,…